Otsuka v. Teva: JYNARQUE Tolvaptan Patents Dismissed Without Prejudice After 885 Days
Otsuka Pharmaceutical filed suit against Teva Pharmaceutical Industries and Teva Pharmaceuticals USA in Delaware District Court, asserting three patents covering tolvaptan — marketed as JYNARQUE — against Teva’s proposed generic tablets. After 885 days of litigation, all claims and counterclaims were dismissed without prejudice, with each party bearing its own costs.
Three Tolvaptan Patents, One Stipulated Exit: Otsuka vs. Teva in Delaware
On 22 April 2022, Otsuka Pharmaceutical Co., Ltd. filed suit against Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc. in the Delaware District Court before Judge Richard G. Andrews. The complaint asserted three U.S. patents — US10905694B2, US8273735B2, and US8501730B2 — covering tolvaptan, the active pharmaceutical ingredient in JYNARQUE, a drug approved for slowing kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). Teva’s proposed generic tolvaptan tablets at 15, 30, 45, 60, and 90 mg strengths were the accused products.
The case closed on 23 September 2024 through a court-approved stipulation dismissing all claims, counterclaims, and affirmative defenses without prejudice. Critically, the Court retained jurisdiction to enforce the stipulated order and any related agreements between the parties — language that strongly suggests a confidential settlement or licensing arrangement was reached alongside the public dismissal. Each party agreed to bear its own attorneys’ fees and costs, which is characteristic of negotiated resolutions rather than adversarial terminations.
At 885 days, the dispute ran well into substantive litigation territory, suggesting meaningful discovery or claim construction activity occurred before the parties reached resolution. The without-prejudice dismissal means Otsuka retains the right to reassert these patents against Teva if any future agreement between the parties breaks down. The precise commercial terms — including any licensing royalties, authorised generic arrangements, or market entry dates — remain confidential and are not reflected in the public record.
Filing to Dismissed without Prejudice in 885 days
885-day litigation — longer than the median ANDA patent dispute in Delaware
Dismissed without prejudice: what the stipulated order means for each party
Without prejudice: no final ruling, full refiling rights preserved
A dismissal without prejudice under Federal Rules of Civil Procedure means the court has made no determination on the merits of any patent claim. Otsuka retains the full legal right to reassert US10905694B2, US8273735B2, and US8501730B2 against Teva in the future. The court’s express retention of jurisdiction to enforce related agreements is a standard feature of stipulated dismissals that accompany confidential settlements.
No merits adjudicationOtsuka exits with patents intact and refiling rights preserved
Because the dismissal is without prejudice, Otsuka’s three tolvaptan patents emerge from this litigation with no adverse validity or infringement finding on record. If a confidential agreement was reached — as the jurisdiction-retention clause suggests — Otsuka likely secured commercial terms governing Teva’s potential market entry. The patents remain enforceable against other ANDA filers who were not party to this action.
Patents survive; terms undisclosedTeva avoids adverse ruling but faces potential future exposure
Teva secured no invalidity or non-infringement judgment from this proceeding. Without a court ruling in its favour, Teva cannot use this case as precedent to support future generic entry challenges to the ‘694, ‘735, or ‘730 patents. Any right to market tolvaptan generics in the U.S. would depend on terms negotiated privately with Otsuka, which the public record does not disclose.
No invalidity ruling securedADPKD market access remains contingent on undisclosed agreement terms
JYNARQUE (tolvaptan) is a high-value branded therapy in a rare disease indication where market exclusivity carries outsized commercial significance. The without-prejudice dismissal, combined with jurisdiction retention, is consistent with a patent settlement that may include a negotiated generic launch date. Other generic manufacturers monitoring this case should note that the Otsuka patents remain unchallenged on the merits and fully enforceable.
Rare disease exclusivity at stakeFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Otsuka Pharmaceutical Co., Ltd. | Company | Originator pharmaceutical company — holder of US10905694B2, US8273735B2 & US8501730B2Search in Eureka ↗ |
| Defendant | Teva Pharmaceutical Industries, Ltd. | Company | Global generic pharmaceutical manufacturer seeking to market tolvaptan tablets in the U.S.Search in Eureka ↗ |
| Co-Defendant | Teva Pharmaceutical Industries, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Teva Pharmaceuticals USA, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | Anna Zhou | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Elaine H. Blais | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Emily DiBenedetto | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Eric T. Romeo | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Gabriel B. Ferrante | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Harrison Gunn | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Jenny J Zhang | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Karen Elizabeth Keller | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Keith A. Zullow | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Madeline R. Bordynoski | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Nathan Roger Hoeschen | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant law firm | Shaw Keller LLP | Law Firm | Representing Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated order dismisses all claims, counterclaims, and affirmative defenses between Otsuka and Teva without prejudice — meaning no court has ruled on the validity, enforceability, or infringement of the ‘694, ‘735, or ‘730 patents. The explicit retention of court jurisdiction to enforce ‘related agreements’ is legally significant: it indicates the parties entered into a separate, likely confidential, agreement whose performance may require future judicial oversight. This structure is entirely consistent with a patent settlement licence governing the timing and conditions of Teva’s potential generic tolvaptan market entry.
US10905694B2, US8273735B2 & US8501730B2 — Tolvaptan formulations for ADPKD
The three asserted patents — US10905694B2 (application no. 12/665,642), US8273735B2 (application no. 12/064,178), and US8501730B2 (application no. 13/474,521) — collectively cover tolvaptan, a selective vasopressin V2-receptor antagonist. Tolvaptan is the active ingredient in JYNARQUE, FDA-approved for slowing kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). The patents span formulation claims, pharmaceutical compositions, and methods of use across a range of dosage strengths (15–90 mg), providing layered exclusivity protection for the JYNARQUE franchise.
ADPKD is a rare, progressive genetic condition affecting approximately 140,000 patients in the U.S., and JYNARQUE represents one of the very few approved pharmacological interventions. The commercial stakes attached to these three patents are therefore disproportionate relative to their nominal claim scope. For generic manufacturers, the multi-patent stack — with differing priority dates and claim architectures — creates a high-complexity FTO landscape. A successful invalidity challenge to even one patent could open a pathway to earlier generic entry, making these patents a strategic target for any ANDA filer in the ADPKD space.
Should your team run an FTO against the Otsuka tolvaptan patents?
Any pharmaceutical company developing a generic, reformulated, or next-generation tolvaptan product — or any vasopressin V2-receptor antagonist targeting ADPKD — should conduct a structured freedom-to-operate analysis against US10905694B2, US8273735B2, and US8501730B2. Because this case was dismissed without prejudice and no invalidity findings are on record, all three patents remain fully enforceable. R&D and regulatory teams working toward an ANDA or 505(b)(2) submission face meaningful infringement risk across multiple claim layers spanning formulation and method-of-use.
PatSnap Eureka’s FTO Search Agent allows IP and R&D professionals to map product specifications against the specific claim language in each of Otsuka’s three tolvaptan patents, identify prosecution history estoppel that may limit claim scope, and surface prior art that could support an invalidity argument. With the Otsuka patent portfolio unchallenged on the merits after this Delaware proceeding, a rigorous, patent-by-patent FTO is the essential first step before any generic tolvaptan development programme advances to filing.
Run a freedom-to-operate analysis on US10905694B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA Patent Cases: Tolvaptan & Rare-Disease Formulation Disputes in Delaware
Browse comparable ANDA infringement actions in Delaware District Court involving rare-disease pharmaceutical formulation patents and stipulated dismissals with jurisdiction retention.
What this case signals for the pharmaceutical patent IP landscape
The Otsuka–Teva tolvaptan dispute illustrates how ANDA patent cases in Delaware frequently resolve through negotiated exits rather than merits rulings.
Without-prejudice exits preserve originator leverage against all future generic filers
Otsuka’s three tolvaptan patents — covering formulations and methods of use — carry no adverse judgment from this case. That means any subsequent ANDA filer challenging these patents faces a pristine litigation record. Originators in rare-disease categories routinely use without-prejudice settlements to maintain this leverage across multiple generic challengers sequentially.
Court jurisdiction retention is a reliable signal of a confidential commercial resolution
When a Delaware District Court dismissal explicitly retains jurisdiction to enforce ‘related agreements,’ this language signals the existence of a side agreement — typically a patent licence or authorised generic deal — whose terms are not public. IP professionals tracking JYNARQUE competitive dynamics should monitor Teva’s ANDA approval status and any FDA Orange Book listing changes for indirect signals of agreed market entry dates.
Otsuka v Teva — key questions answered
Otsuka asserted three U.S. patents: US10905694B2, US8273735B2, and US8501730B2. All three cover tolvaptan — the active ingredient in JYNARQUE tablets — including pharmaceutical formulations and methods of use for treating autosomal dominant polycystic kidney disease (ADPKD). Teva’s accused products were proposed generic tolvaptan tablets at 15, 30, 45, 60, and 90 mg strengths.
A dismissal without prejudice means no court made any finding on the validity, enforceability, or infringement of Otsuka’s three tolvaptan patents. The patents remain fully enforceable. Otsuka retains the right to reassert them against Teva or any other party in future litigation. No invalidity precedent was established that other generic ANDA filers could rely upon.
The stipulation’s express retention of Delaware District Court jurisdiction to enforce ‘related agreements resolving this matter’ strongly suggests a confidential agreement — likely a patent licence or authorised generic arrangement — was negotiated alongside the dismissal. This is a standard structural feature of patent settlements in Hatch-Waxman ANDA litigation. The specific commercial terms are not disclosed in the public court record.
The case was filed in the U.S. District Court for the District of Delaware and assigned to Judge Richard G. Andrews. Delaware is the most common venue for Hatch-Waxman ANDA patent litigation in the United States, and Judge Andrews is one of its most experienced patent jurists. The case ran from 22 April 2022 to 23 September 2024 — a total of 885 days.
The public court record does not answer this definitively. No court ruled that Teva’s products are non-infringing or that Otsuka’s patents are invalid. Any right Teva may have to market generic tolvaptan would depend on terms negotiated privately with Otsuka or on FDA regulatory approval status. Parties monitoring competitive entry into the JYNARQUE market should track FDA Orange Book listings and any public statements from Otsuka or Teva regarding authorised generic agreements.
PatSnap Eureka searches patents and litigation data to answer instantly.